Advertisement

Chronic Administration of 1-Methyl-4-Phenyl-1,2,3,6- Tetrahydropyridine to Marmosets

  • Alberto Albanese
  • Maria Concetta Altavista
  • Carlo Colosimo
  • Anna Rita Bentivoglio
  • Paola Rossi
  • Giorgio Macchi
Part of the Advances in Behavioral Biology book series (ABBI, volume 39)

Abstract

It is well established that the administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) to human beings or to non-human primates brings about a parkinsonian syndrome which closely resembles idiopathic Parkinson’s disease (Snyder and D’Amato, 1986). With few noticeable exceptions (Langston and Ballard 1983), the human cases of accidental exposure to MPTP were caused by acute administration of this toxin (i.e., a single or few repeated injections; Langston, 1987). Similarly, in order to obtain experimental animals which are clinically affected, monkeys are usually injected with repeated doses of MPTP over 2 to 5 days. Regimen varies according to the species. In marmosets, 4–5 daily injections of 1–4 mg/kg/day i.p. are effective so as to obtain animals which are obviously parkinsonian, but who can maintain themselves (Jenner et al., 1984). The resemblance of MPTP-induced parkinsonism to Parkinson’s disease is still an unsolved issue (Albanese 1989). Recently, Kish et al. (1988) found that, in patients affected by Parkinson’s disease, dopamine loss is more severe in the putamen than in the caudate nucleus, while in monkeys poisoned acutely with MPTP dopamine loss is higher in the caudate nucleus than in the putamen.

Keywords

Tyrosine Hydroxylase Substantia Nigra Chronic Administration Common Marmoset Parkinsonian Syndrome 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Albanese A., in press, Extrapyramidal system, motor ganglia and movement disorders, Reviews in the Neurosciences Google Scholar
  2. Albanese A., Altavista M.C., Gozzo S., Rossi P., Colosimo C., Bentivoglio A.R., Perretta G., Elia M., Monaco V., Macchi G., in press, Chronic administration of MPTP to marmosets, Adv. Neurol. Google Scholar
  3. Barbeau A., Roy M., Cloutier T., Plasse L., Paris S, 1986, Environmental and genetic factors in the etiology of Parkinson’s disease, in: “Parkinson’s disease”, M. Yahr, K.J. Bergmann, Eds., Raven, New York, Adv. Neurol. 45: 299Google Scholar
  4. Eidelberg E., Brooks B.A., Morgan W.W., Walden J.G., Kokemoor R.H., 1986, Variability and functional recovery in the N-methyl-4-phenyl-1,2,3,6tetrahydropyridine model of parkinsonism in monkeys, Neuroscience 18: 817.PubMedCrossRefGoogle Scholar
  5. Jenner P., Marsden C.D., 1986, The actions of 1-methyl-4-phenyl-1,2,3,6tetrahydropyridine in animals as a model of Parkinson’s disease, J. Neural Transm. Suppl. 20: 11.PubMedGoogle Scholar
  6. Jenner P., Rupniak N.M.J., Rose S., Kelly E., Kilpatrik G., Lees A., Marsden C.D., 1984, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in the common marmoset, Neurosci Lett. 50: 85.Google Scholar
  7. Jenner P., Rose S., Nomoto M., Marsden C.D., 1986, MPTP-induced parkinsonism in the common marmoset: behavioral and biochemical effects, in: “Parkinson’s disease”, M.D. Yahr, K.J. Bergmann, Eds., Raven, New York, Adv. Neurol.45: 183Google Scholar
  8. Kish S.J., Shannak K., Hornykiewicz 0., 1988, Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson’s disease, N. Engl. J. Med. 318: 876.Google Scholar
  9. Lams B.E., Isacson 0., Sofroniew M.V., 1988, Loss of transmitter-associated enzyme staining following axotomy does not indicate death of brainstem cholinergic neurons, Brain Res. 475: 401.PubMedGoogle Scholar
  10. Langston J.W., 1987, MPTP: the promise of a new neurotoxin, in: “Movement Disorders 2”, C.D. Marsden, S. Fahn, Eds., Butterworths, London.Google Scholar
  11. Langston J.W., Ballard P.A., 1983, Parkinson’s disease in a chemist working with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine, New Engl. J. Med. 4: 310.Google Scholar
  12. Rajput A.H., Uitti R.J., Stern W., Laverty W., 1986, Early onset Parkinson’s disease and the childhood environment, in: “Parkinson’s disease”, M. Yahr, K.J. Bergmann, Eds., Raven, New York, Adv. Neurol., 45: 295Google Scholar
  13. Snyder S.H., D’Amato R.J., 1986, MPTP: a neurotoxin relevant to the pathophysiology of Parkinson’s disease, Neurology 36: 250.PubMedCrossRefGoogle Scholar

Copyright information

© Plenum Press, New York 1991

Authors and Affiliations

  • Alberto Albanese
    • 1
  • Maria Concetta Altavista
    • 1
  • Carlo Colosimo
    • 1
  • Anna Rita Bentivoglio
    • 1
  • Paola Rossi
    • 1
  • Giorgio Macchi
    • 1
  1. 1.Istituto di NeurologiaUniversità Cattolica del Sacro CuoreRomaItaly

Personalised recommendations